ITCA 650

DRUG4 trials

Sponsors

Intarcia Therapeutics

Conditions

Type 2 Diabetes

Phase 2

Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus

CompletedNCT00943917

Intarcia TherapeuticsType 2 Diabetes

Start: 2009-08-31End: 2011-02-28Updated: 2015-04-13

Phase 3

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

CompletedNCT01455896

Intarcia TherapeuticsType 2 Diabetes

Start: 2013-03-31End: 2016-03-31Updated: 2017-01-27

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

CompletedNCT01455857

Intarcia TherapeuticsType 2 Diabetes

Start: 2013-03-31End: 2014-09-30Updated: 2015-08-18

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

WithdrawnNCT01455922

Intarcia TherapeuticsType 2 Diabetes

Start: 2013-02-28End: 2014-07-31Updated: 2012-12-25

Related Papers

Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial.

2021-12-0664 citations

Implications of cardiovascular outcome trials with injectable antidiabetic agents

Journal of Diabetes2018-07-044 citations